Valeo Financial Advisors LLC Cuts Holdings in Sanofi (NASDAQ:SNY)

Valeo Financial Advisors LLC reduced its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 62.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,496 shares of the company's stock after selling 8,976 shares during the quarter. Valeo Financial Advisors LLC's holdings in Sanofi were worth $265,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC increased its position in shares of Sanofi by 30.6% in the fourth quarter. V Square Quantitative Management LLC now owns 13,557 shares of the company's stock valued at $657,000 after buying an additional 3,179 shares in the last quarter. McClarren Financial Advisors Inc. grew its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Van ECK Associates Corp grew its stake in Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock valued at $31,965,000 after acquiring an additional 101,726 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Sanofi by 128.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company's stock valued at $5,558,000 after acquiring an additional 64,747 shares in the last quarter. Finally, Kentucky Trust Co acquired a new position in Sanofi during the fourth quarter worth about $436,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.6 %

Shares of NASDAQ SNY traded up $0.33 during midday trading on Friday, reaching $54.46. 1,424,158 shares of the stock were exchanged, compared to its average volume of 2,441,240. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $138.21 billion, a P/E ratio of 21.87, a P/E/G ratio of 1.00 and a beta of 0.57. The stock has a 50 day moving average price of $50.95 and a 200-day moving average price of $52.52. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.